Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in Non-small Cell Lung Cancer (NSCLC) With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer (CRC)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
11 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Yale University
New Haven, Connecticut, United States
- Emory University
Atlanta, Georgia, United States
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, United States
- University of Maryland, Marlene and Stewart Greenbaum Cancer Center
Baltimore, Maryland, United States
- Dana Farber Cancer Institution
Boston, Massachusetts, United States
- Roswell Park Cancer Institute
Buffalo, New York, United States
- Memorial Sloan Kettering Cancer Center
New York, New York, United States
- the University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States
- St Luke'S University Health Network
Easton, Pennsylvania, United States
- Sarah Cannon Research Institute
Nashville, Tennessee, United States
- Vanderbilt University Medical Center
Nashville, Tennessee, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 26 Aug 2015
- Primary completion
- 29 Sept 2022
- Completion
- 29 Sept 2022
- Last update posted
- 20 Mar 2025
- Registered enrollment
- 191
- Registry id
- NCT02437136
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.